Catalyst Pharmaceuticals Inc (CPRX.OQ) Key Developments | Reuters.com
Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

0.79USD
24 Jun 2016
Change (% chg)

-- (--)
Prev Close
$0.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
248,418
52-wk High
$5.80
52-wk Low
$0.51

Latest Key Developments (Source: Significant Developments)

Catalyst Pharma finalizes late-stage trial design with FDA for Firdapse
Monday, 13 Jun 2016 08:31am EDT 

Catalyst Pharmaceuticals Inc : Catalyst Pharmaceuticals announces agreement with FDA on confirmatory phase 3 study protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome . Expects to initiate a small, single-center study with Firdapse during second half of 2016 .Existing capital resources are adequate to get us to an accepted NDA submission without need for additional financing.  Full Article

Catalyst Pharmaceuticals announces reduction in workforce
Tuesday, 17 May 2016 08:03am EDT 

Catalyst Pharmaceuticals Inc : Announces reduction in workforce as part of operating expense management plan . Reducing its workforce by approximately 30% . Expects to complete reduction in workforce immediately . Reduction in workforce affects employees from Catalyst's commercial team . Believe currently available resources will be sufficient to complete development of and refile NDA for firdapse for lems, cms .Reduction in workforce is part of ongoing efforts to conserve cash to complete requirements for NDA submission of Firdapse.  Full Article

Catalyst Pharmaceuticals posts Q1 GAAP loss of $0.07/shr
Tuesday, 10 May 2016 04:56pm EDT 

Catalyst Pharmaceuticals Inc : Believe current resources give sufficient runway for at least next year . Continue to believe available resources will be sufficient to complete development of firdapse, refile nda for firdapse . Catalyst pharmaceuticals announces first quarter 2016 financial results and provides corporate update . Q1 gaap loss per share $0.07 . Q1 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S .Q1 non-gaap loss per share $0.07 excluding items.  Full Article

Catalyst Pharmaceuticals announces top-line results in Phase 1 Trial of CPP-115
Wednesday, 16 Dec 2015 08:36am EST 

Catalyst Pharmaceuticals Inc:Says main adverse effect of prolonged elevated brain gaba, somnolence, was also observed.Results showed significant increases in brain levels of surrogate marker for potential efficacy, gamma-aminobutyric acid.Says expect to receive the full results of this study early next year.  Full Article

Catalyst Pharmaceuticals announces intent to develop generic equivalent of Sabril
Wednesday, 9 Sep 2015 08:03am EDT 

Catalyst Pharmaceuticals Inc:Announced the initiation of a project to develop a generic equivalent of Sabril.  Full Article

Catalyst Pharmaceuticals announces FDA Orphan Drug Designation of Firdapse for Treatment of Congenital Myasthenic Syndromes
Thursday, 5 Mar 2015 10:35am EST 

Catalyst Pharmaceutical Partners Inc:Says the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for Firdapse(tm) for treatment of patients with Congenital Myasthenic Syndromes (CMS).  Full Article

Catalyst Pharmaceutical Partners Inc announces closing of previously announced public offering
Monday, 9 Feb 2015 10:10am EST 

Catalyst Pharmaceutical Partners Inc:Closes its public offering of shares of its common stock.Sold 11,500,000 shares of its common stock in the offering, which includes 1,500,000 shares that were issued upon the full exercise by the underwriters of their over-allotment option.Offering price was $3.25 per share, and the net proceeds from the sale of the shares is expected to be about $34.7 mln.Piper Jaffray & Co. acted as the sole lead book-running manager and SunTrust Robinson Humphrey acted as the passive book-running manager with respect to this offering.Further, Roth Capital Partners and H.C. Wainwright & Co. acted as the lead co-manager and co-manager, respectively.  Full Article

Catalyst Pharmaceutical Partners Inc. prices public offering of common stock
Wednesday, 4 Feb 2015 09:00am EST 

Catalyst Pharmaceutical Partners Inc:Pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at an offering price of $3.25 per share.In connection with the offering, Catalyst has also granted the underwriters 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any.Net proceeds from the sale of the shares by Catalyst after underwriting discounts and commissions and other offering expenses are expected to be about $30.1 mln.Catalyst plans to use the net proceeds from the offering to pay milestone payments due on final approval of an NDA for Firdapse; to pay pre commercialization and other expenses required to launch Firdapse.Also uses to fund future clinical studies of Firdapse for other indications, to the extent that such additional studies are required; to fund future clinical and nonclinical studies of CPP-115; and for general corporate purposes.The offering is subject to customary closing conditions and is expected to close on Feb. 9.Piper Jaffray & Co. is acting as the sole lead book-running manager and SunTrust Robinson Humphrey is acting as the passive book-running manager with respect to this offering.Further, Roth Capital Partners and H.C. Wainwright & Co. are acting as the lead co-manager and co-manager, respectively.  Full Article

Catalyst Pharmaceutical Partners Inc announces commencement of public offering of common stock
Tuesday, 3 Feb 2015 04:40pm EST 

Catalyst Pharmaceutical Partners Inc:Intends to offer shares of its common stock in a public offering.Also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any.Plans to use the net proceeds from the offering to pay milestone payments due on final approval of an NDA for Firdapse, to pay pre-commercialization and other expenses required to launch Firdapse.Also uses to fund future clinical studies of Firdapse for other indications, to the extent that such additional studies are required.Also to fund future clinical and nonclinical studies of CPP-115 and for general corporate purposes.Piper Jaffray & Co. is acting as the sole lead book-running manager and SunTrust Robinson Humphrey is acting as the passive book-running manager.  Full Article

Catalyst Pharmaceuticals Partners Inc proposes settlement of pending securities class action lawsuit
Tuesday, 4 Nov 2014 08:03am EST 

Catalyst Pharmaceuticals Partners Inc:Says that it has entered into a memorandum of understanding to settle its pending class action securities lawsuit.As previously disclosed, the company and one of its executive officers are defendants in a class action lawsuit filed in the U.S. District Court for the Southern District of Florida.Amended complaint purports to state a claim for alleged misrepresentations regarding the development of Firdapse(tm) on behalf of a class of those who purchased shares of the company's common stock between Aug. 27, 2013 and Oct. 18, 2013.  Full Article

BRIEF-Catalyst Pharma finalizes late-stage trial design with FDA for Firdapse

* Catalyst Pharmaceuticals announces agreement with FDA on confirmatory phase 3 study protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome